The Food and Drug Administration granted Breakthrough Therapy Designation to Seattle Genetics Inc.'s (Nasdaq: SGEN) ADCETRIS in combination with chemotherapy for the frontline treatment of advanced classical Hodgkin lymphoma. Shares of the biotechnology firm soared $4.31 to close at $58.72.
Breakthrough Therapy Designation granted to Seattle Genetics
October 02, 2017 at 20:02 PM EDT
